Since the specific sensitivity of tumors with BRCA1/2 mutations to platinum therapy was described in breast cancer and ovarian cancer31,32, we expected the effects to be identical in ESCC. The gene discussed is BRCA1; the disease is esophageal squamous cell carcinoma.